{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:52:43Z","timestamp":1794556363456,"version":"4.9.1"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"Importance<\/jats:title>Increases in pulmonary capillary wedge pressure (PCWP) during exercise reduce pulmonary artery (PA) compliance, increase pulsatile right ventricular (RV) afterload, and impair RV-PA coupling in patients with heart failure with preserved ejection fraction (HFpEF). The effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin on pulmonary vascular properties and RV-PA coupling are unknown.<\/jats:p><\/jats:sec>Objective<\/jats:title>To test the effect of dapagliflozin on right ventricular performance and pulmonary vascular load during exertion in HFpEF.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>Evaluation of the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction (CAMEO-DAPA) randomized clinical trial demonstrated improvement in PCWP at rest and exercise over 24 weeks with dapagliflozin compared with placebo with participants recruited between February 2021 and May 2022. This secondary analysis evaluates the effects of dapagliflozin on pulsatile pulmonary vascular load and RV-PA coupling using simultaneous echocardiography and high-fidelity invasive hemodynamic testing with exercise. This was a single-center study including patients with hemodynamically confirmed HFpEF with exercise PCWP of 25 mm Hg or greater.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Dapagliflozin or placebo for 24 weeks.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Pulsatile pulmonary vascular load (PA compliance and elastance) and right ventricular performance (PA pulsatility index, RV systolic velocity [s\u2032]\/PA mean) during rest and exercise.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 37 randomized participants (mean [SD] age, 67.4 [8.5] years; 25 female [65%]; mean [SD] body mass index, 34.9 [6.7]; calculated as weight in kilograms divided by height in meters squared), there was no effect of dapagliflozin on PA loading or RV-PA interaction at rest. However, with exercise, dapagliflozin improved PA compliance (placebo-corrected mean difference, 0.57 mL\/mm Hg; 95% CI, 0.11-1.03 mL\/mm Hg; P<\/jats:italic>\u2009=\u2009.02) and decreased PA elastance (stiffness; \u22120.17 mm Hg\/mL; 95% CI, \u22120.28 to \u22120.07 mm Hg\/mL; P<\/jats:italic>\u2009=\u2009.001). RV function during exercise improved, with increase in PA pulsatility index (0.33; 95% CI, 0.08-0.59; P<\/jats:italic>\u2009=\u2009.01) and increase in exercise RV s\u2032 indexed to PA pressure (0.09 cm\u00b7s\u22121<\/jats:sup>\/mm Hg; 95% CI, 0.02-0.16 cm\u00b7s\u22121<\/jats:sup>\/mm Hg; P<\/jats:italic>\u2009=\u2009.01). Improvements in pulsatile RV load and RV-PA coupling were correlated with reduction in right atrial (RA) pressure (PA elastance Pearson r<\/jats:italic> = 0.55; P<\/jats:italic> =.008; RV s\u2032\/PA elastance Pearson r<\/jats:italic> = \u22120.60; P<\/jats:italic> =.002) and PCWP (PA elastance Pearson r<\/jats:italic> = 0.58; P<\/jats:italic> &amp;lt;.001; RV s\u2032\/PA elastance Pearson r <\/jats:italic>= \u22120.47; P<\/jats:italic> = .02). Dapagliflozin increased resistance-compliance time (dapagliflozin, median [IQR] change, 0.06 [0.03-0.15] seconds; placebo, median [IQR] change, 0.01 [\u22120.02 to 0.05] seconds; P<\/jats:italic> =.046), resulting in higher PA compliance for any exercise pulmonary vascular resistance.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Results of this randomized clinical trial reveal that treatment with dapagliflozin for 24 weeks reduced pulsatile pulmonary vascular load and enhanced dynamic RV-PA interaction during exercise in patients with HFpEF, findings that are related to the magnitude of PCWP reduction. Benefits on dynamic right ventricular\u2013pulmonary vascular coupling may partially explain the benefits of SGLT2 inhibitors in HFpEF.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT04730947<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2024.1914","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T16:19:55Z","timestamp":1721837995000},"page":"843","source":"Crossref","is-referenced-by-count":60,"title":["Dapagliflozin and Right Ventricular\u2013Pulmonary Vascular Interaction in Heart Failure With Preserved Ejection Fraction"],"prefix":"10.1001","volume":"9","author":[{"given":"Yogesh N. V.","family":"Reddy","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic and Foundation, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rickey E.","family":"Carter","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Division of Clinical Trials & Biostatistics, Mayo Clinic, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemi","family":"Sorimachi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic and Foundation, Rochester, Minnesota"},{"name":"Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massar","family":"Omar","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic and Foundation, Rochester, Minnesota"},{"name":"Department of Cardiology, Odense University Hospital, Odense, Denmark"},{"name":"Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejana","family":"Popovic","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic and Foundation, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Alogna","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic and Foundation, Rochester, Minnesota"},{"name":"Deutsches Herzzentrum der Charit\u00e9, Department of Cardiology, Angiology and Intensive Care Medicine, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry A.","family":"Borlaug","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic and Foundation, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"hoi240039r1","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart failure with mildly reduced or preserved ejection fraction.","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"hoi240039r2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"hoi240039r3","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"hoi240039r4","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.123.065134","article-title":"Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: the CAMEO-DAPA trial.","volume":"148","author":"Borlaug","year":"2023","journal-title":"Circulation"},{"issue":"30","key":"hoi240039r5","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1093\/eurheartj\/ehy268","article-title":"Hemodynamics, dyspnea, and pulmonary reserve in heart failure with preserved ejection fraction.","volume":"39","author":"Obokata","year":"2018","journal-title":"Eur Heart J"},{"issue":"8","key":"hoi240039r6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jchf.2018.03.003","article-title":"Hemodynamic correlates and diagnostic role of cardiopulmonary exercise testing in heart failure with preserved ejection fraction.","volume":"6","author":"Reddy","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"45","key":"hoi240039r7","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1093\/eurheartj\/ehz713","article-title":"The hemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction.","volume":"40","author":"Reddy","year":"2019","journal-title":"Eur Heart J"},{"issue":"2","key":"hoi240039r8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ejhf.2747","article-title":"Central hemodynamic abnormalities and outcome in patients with unexplained dyspnea.","volume":"25","author":"Omote","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"13","key":"hoi240039r9","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.jacc.2008.11.051","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study.","volume":"53","author":"Lam","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"hoi240039r10","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/eurheartj\/ehy809","article-title":"Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction.","volume":"40","author":"Obokata","year":"2019","journal-title":"Eur Heart J"},{"issue":"48","key":"hoi240039r11","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1093\/eurheartj\/ehu193","article-title":"Right heart dysfunction in heart failure with preserved ejection fraction.","volume":"35","author":"Melenovsky","year":"2014","journal-title":"Eur Heart J"},{"issue":"6","key":"hoi240039r12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jacc.2023.05.010","article-title":"Right ventricular function and pulmonary coupling in patients with heart failure and preserved ejection fraction.","volume":"82","author":"Inciardi","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"43","key":"hoi240039r13","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1093\/eurheartj\/ehw241","article-title":"Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction.","volume":"37","author":"Borlaug","year":"2016","journal-title":"Eur Heart J"},{"issue":"3","key":"hoi240039r14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cardfail.2017.11.003","article-title":"Pulmonary vascular resistance during exercise predicts long-term outcomes in heart failure with preserved ejection fraction.","volume":"24","author":"Huang","year":"2018","journal-title":"J Card Fail"},{"issue":"2","key":"hoi240039r15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.111.051540","article-title":"Pulmonary capillary wedge pressure augments right ventricular pulsatile loading.","volume":"125","author":"Tedford","year":"2012","journal-title":"Circulation"},{"issue":"8","key":"hoi240039r16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1161\/CIRCULATIONAHA.121.053889","article-title":"Metabolic syndrome mediates ROS-miR-193b-NFYA-dependent downregulation of soluble guanylate cyclase and contributes to exercise-induced pulmonary hypertension in heart failure with preserved ejection fraction.","volume":"144","author":"Satoh","year":"2021","journal-title":"Circulation"},{"issue":"2","key":"hoi240039r17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1161\/CIRCRESAHA.118.313832","article-title":"The \u00df-adrenergic agonist albuterol improves pulmonary vascular reserve in heart failure with preserved ejection fraction.","volume":"124","author":"Reddy","year":"2019","journal-title":"Circ Res"},{"issue":"15","key":"hoi240039r18","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/j.jacc.2015.07.067","article-title":"Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction.","volume":"66","author":"Borlaug","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"hoi240039r19","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1161\/CIRCRESAHA.116.309184","article-title":"Inhaled sodium nitrite improves rest and exercise hemodynamics in heart failure with preserved ejection fraction.","volume":"119","author":"Borlaug","year":"2016","journal-title":"Circ Res"},{"issue":"38","key":"hoi240039r20","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"issue":"13","key":"hoi240039r21","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/eurheartj\/ehn103","article-title":"Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension.","volume":"29","author":"Lankhaar","year":"2008","journal-title":"Eur Heart J"},{"issue":"2","key":"hoi240039r22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/ejhf.2084","article-title":"Pulmonary artery pulsatility index predicts right ventricular myofilament dysfunction in advanced human heart failure.","volume":"23","author":"Aslam","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"36","key":"hoi240039r23","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1093\/eurheartj\/ehac184","article-title":"Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications.","volume":"43","author":"Omote","year":"2022","journal-title":"Eur Heart J"},{"key":"hoi240039r24","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.jcmg.2016.12.024","article-title":"RV contractile function and its coupling to pulmonary circulation in heart failure with preserved ejection fraction: stratification of clinical phenotypes and outcomes.","volume":"10","author":"Guazzi","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"issue":"9","key":"hoi240039r25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.119.009047","article-title":"Validation of the tricuspid annular plane systolic excursion\/systolic pulmonary artery pressure ratio for the assessment of right ventricular-arterial coupling in severe pulmonary hypertension.","volume":"12","author":"Tello","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"issue":"2","key":"hoi240039r26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004121","article-title":"Load-independent systolic and diastolic right ventricular function in heart failure with preserved ejection fraction as assessed by resting and handgrip exercise pressure-volume loops.","volume":"11","author":"Rommel","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"9","key":"hoi240039r27","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1161\/CIRCULATIONAHA.120.052414","article-title":"Reduced right ventricular sarcomere contractility in heart failure with preserved ejection fraction and severe obesity.","volume":"143","author":"Aslam","year":"2021","journal-title":"Circulation"},{"issue":"21","key":"hoi240039r28","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1161\/CIRCULATIONAHA.121.054858","article-title":"Energetic basis for exercise-induced pulmonary congestion in heart failure with preserved ejection fraction.","volume":"144","author":"Burrage","year":"2021","journal-title":"Circulation"},{"issue":"21","key":"hoi240039r29","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1161\/CIRCULATIONAHA.122.059486","article-title":"Latent pulmonary vascular disease may alter the response to therapeutic atrial shunt device in heart failure.","volume":"145","author":"Borlaug","year":"2022","journal-title":"Circulation"},{"issue":"7","key":"hoi240039r30","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1093\/eurjhf\/hft026","article-title":"Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction.","volume":"15","author":"Abudiab","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"hoi240039r31","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/ejhf.1788","article-title":"Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity.","volume":"22","author":"Reddy","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"hoi240039r32","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","article-title":"The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.","volume":"28","author":"Spertus","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"hoi240039r33","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jacc.2022.11.006","article-title":"Effect of dapagliflozin on health status in patients with preserved or mildly reduced ejection fraction.","volume":"81","author":"Kosiborod","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"hoi240039r34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.122.059725","article-title":"Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: results from the EMPULSE trial.","volume":"146","author":"Kosiborod","year":"2022","journal-title":"Circulation"},{"issue":"3","key":"hoi240039r35","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.121.057812","article-title":"Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR preserved trial.","volume":"145","author":"Butler","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"hoi240039r36","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/eurheartj\/ehaa943","article-title":"Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.","volume":"42","author":"Abraham","year":"2021","journal-title":"Eur Heart J"},{"issue":"11","key":"hoi240039r37","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.123.065061","article-title":"Effect of dapagliflozin vs placebo on symptoms and 6-minute walk distance in patients with heart failure: the DETERMINE randomized clinical trials.","volume":"149","author":"McMurray","year":"2024","journal-title":"Circulation"},{"issue":"11","key":"hoi240039r38","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/CIRCULATIONAHA.123.068089","article-title":"Nature and magnitude of the benefits of dapagliflozin and empagliflozin for heart failure.","volume":"149","author":"Cleland","year":"2024","journal-title":"Circulation"},{"issue":"36","key":"hoi240039r39","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1093\/eurheartj\/ehac389","article-title":"Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial.","volume":"43","author":"Dachs","year":"2022","journal-title":"Eur Heart J"},{"issue":"15","key":"hoi240039r40","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/eurheartj\/ehx700","article-title":"Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.","volume":"39","author":"Bermejo","year":"2018","journal-title":"Eur Heart J"},{"issue":"48","key":"hoi240039r41","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1093\/eurheartj\/ehac495","article-title":"Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR program.","volume":"43","author":"Zannad","year":"2022","journal-title":"Eur Heart J"},{"issue":"8 Pt 2","key":"hoi240039r42","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jchf.2023.01.030","article-title":"Exercise-induced left atrial hypertension in heart failure with preserved ejection fraction.","volume":"11","author":"Litwin","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"20","key":"hoi240039r43","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1093\/eurheartj\/ehab911","article-title":"Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality.","volume":"43","author":"Verbrugge","year":"2022","journal-title":"Eur Heart J"},{"issue":"10","key":"hoi240039r44","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.mayocp.2023.07.008","article-title":"Obesity, cardiorenal comorbidities, and risk of hospitalization in patients with heart failure with preserved ejection fraction.","volume":"98","author":"Morgen","year":"2023","journal-title":"Mayo Clin Proc"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2821144\/jamacardiology_reddy_2024_oi_240039_1725982855.026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T15:36:32Z","timestamp":1726068992000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2821144"}},"subtitle":["A Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2024.1914","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}